Midodrine for Hypotension in Patients Receiving Diuretics

Critical Safety Concerns in Dialysis Patients

Meta-analyses show midodrine improves nadir systolic blood pressure by 13 mmHg (95% CI: 9-18 mmHg) and reduces intradialytic hypotension symptoms in dialysis patients, but these studies were small and examined no clinical endpoints like death or cardiovascular events, according to the KDIGO guidelines 1, 2, 3
Observational data from matched cohorts found midodrine use was associated with significantly higher risks of cardiovascular events, all-cause hospitalization, and mortality when compared to non-users matched by peridialytic blood pressure levels in dialysis patients 1, 2, 3

Continuation of loop diuretics after hemodialysis initiation is associated with lower interdialytic weight gain and paradoxically lower intradialytic hypotension rates, suggesting diuretics themselves may be protective rather than problematic in this population 1, 2

The MACHT trial (2024), a placebo-controlled study in cirrhosis patients, found no differences in mortality or complications when albumin plus midodrine was compared to double placebo 6
Midodrine should not be used in the management of uncomplicated ascites, after large-volume paracentesis, or in patients with spontaneous bacterial peritonitis, as evidence is insufficient and some data suggest increased acute kidney injury risk 6

The evidence does not support routine use of midodrine in patients receiving diuretics for hypotension management, as it may worsen outcomes in terms of cardiovascular events and mortality in dialysis patients, and evidence is insufficient or negative in non-dialysis settings 1, 2, 3, 6